以复发肿瘤分级指导卡介苗治疗中的后续治疗:低级别复发并非良性
该研究回顾性分析了146例在卡介苗(BCG)治疗期间出现非肌层浸润性膀胱癌(NMIBC)复发的患者,其中低级别复发38例、高级别复发108例。结果显示低级别复发患者的无进展生存、无复发生存、高级别无复发生存及免膀胱切除生存均优于高级别复发者,但低级别复发患者估计5年进展率仍达14.4%。作者认为复发肿瘤分级是进展至肌层浸润性膀胱癌或转移的独立预测因素,所有患者均应就保留膀胱治疗进行审慎咨询。
要点
- BCG治疗期间NMIBC复发患者中,低级别复发者无进展生存优于高级别复发者(5年PFS 85.6% vs 67.9%,p=0.010)。
- 低级别复发患者估计5年进展率仍为14.4%,提示低级别复发并非良性。
- 复发肿瘤分级是进展至MIBC/远处转移的独立预测因素(HR 3.60,95%CI 1.18-10.94,p=0.024)。
核心结论
- BCG膀胱内治疗后肿瘤复发分级是膀胱癌进展至肌层浸润性膀胱癌/转移性尿路上皮癌的重要预测因素。
- 低级别复发患者进展事件数不到高级别复发患者的一半,但其估计5年进展率仍为14.4%。
- 因此所有患者均应就保留膀胱治疗进行审慎咨询,这对临床试验设计也有启示。
研究设计与样本
- 经机构审查委员会批准的膀胱癌数据库回顾性分析。
- 共146例非肌层浸润性膀胱癌患者在BCG治疗期间出现NMIBC复发,其中低级别复发38例、高级别复发108例。
- 评估基线临床病理特征包括年龄、性别、原发肿瘤分级、分期、大小、多发性及合并原位癌。
- 主要终点为无进展生存(PFS),进展定义为发生肌层浸润性膀胱癌/远处转移;同时比较无复发生存(RFS)、高级别无复发生存(HG RFS)、免膀胱切除生存(CFS)和癌症特异性生存(CSS)。
- 采用Cox回归模型进行多变量分析,所有检验均为双侧,p<0.05为统计学显著。
主要发现
- 总体估计5年PFS为72.4%(95%CI 60.4-81.3%)。
- 按复发肿瘤分级二分,低级别复发患者PFS为85.6%(95%CI 60.8-95.2%),高于高级别复发患者的67.9%(95%CI 54.1-78.4%),p=0.010。
- 低级别初始复发患者后续RFS中位62个月 vs 高级别初始复发患者34个月(p=0.007),HG RFS中位112个月 vs 36个月(p<0.001),估计5年CFS 80.8% vs 49.8%(p<0.001)。
- 单变量和多变量分析中,BCG治疗后肿瘤复发分级是进展至MIBC/远处转移时间的独立预测因素(HR 3.60,95%CI 1.18-10.94,p=0.024)。
临床怎么用
- 作者认为,BCG治疗后肿瘤复发分级是膀胱癌进展至MIBC/转移性尿路上皮癌的重要预测因素。
- 作者指出,低级别复发患者进展事件数不到高级别复发患者的一半,但其估计5年进展率仍为14.4%,因此所有患者均应就保留膀胱治疗进行审慎咨询。
- 作者认为该结果对临床试验设计也有启示。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumors that recur after bacillus Calmette-Guerin (BCG) therapy are considered to be of very high risk, and patients are often recommended to undergo radical cystectomy (RC). However, the nuances associated with the grade of tumor recurrence after BCG treatment are not well understood. OBJECTIVE: To characterize the pattern of bladder cancer progression and cancer-specific survival (CSS) in patients with recurrences dichotomized by low grade (LG) versus high grade (HG) after intravesical BCG treatment, and to assess the safety of continued bladder-sparing therapy in these patients. DESIGN, SETTING, AND PARTICIPANTS: We performed an Institutional Review Board-approved review of our bladder cancer database. Overall, 146 non-muscle-invasive bladder cancer (NMIBC) patients were found to have NMIBC recurrence while on BCG therapy; this recurrence was LG in 38 and HG in 108. Baseline clinicopathologic characteristics including age, gender, primary tumor grade, stage, size, multiplicity, and concurrent carcinoma in situ were also evaluated. The primary endpoint was progression-free survival (PFS), with progression defined as the development of muscle-invasive bladder cancer (MIBC)/distant metastasis. In addition, recurrence-free survival (RFS), HG RFS, cystectomy-free survival (CFS), and CSS were also compared. Multivariable analysis was performed using the Cox regression model. All tests were two sided, and p<0.05 was considered statistically significant. INTERVENTION: Further intravesical therapy versus salvage RC. RESULTS AND LIMITATIONS: Overall, estimated 5-yr PFS was 72.4% (95% confidence interval [CI] 60.4-81.3%). As dichotomized by grade of recurrent tumor, PFS was greater for patients with LG recurrences (85.6%, 95% CI 60.8-95.2%) than for those with HG recurrence (67.9%, 95% CI 54.1-78.4%; p=0.010). Furthermore, patients whose initial recurrence on BCG therapy was LG had improved subsequent RFS (median 62 vs 34mo, p=0.007), HG RFS (median 112 vs 36mo, p<0.001), and CFS (estimated 5-yr CFS 80.8% vs 49.8%, p<0.001) compared with those who had HG initial recurrence. On univariate and multivariate analyses, grade of tumor recurrence after BCG was an independent predictor of time to progression to MIBC/distant metastasis (hazard ratio 3.60, 95% CI 1.18-10.94, p=0.024). CONCLUSIONS: Grade of tumor recurrence after intravesical BCG is an important predictor of bladder cancer progression to MIBC/metastatic urothelial carcinoma. While, patients with LG recurrences have less than half the progression events compared with those with HG recurrences, their estimated 5-yr progression rate is still 14.4%. Hence all patients should be carefully counseled on bladder-sparing therapy. This also has implications for clinical trial design. PATIENT SUMMARY: If bladder cancer recurs after bacillus Calmette-Guerin treatment, there are many factors that determine the further clinical outcome. Although low-grade recurrent tumors confer a less aggressive course, disease progression can still occur, and hence continued vigilance is important.
引用
- Li R, Metcalfe MJ, Tabayoyong WB, et al. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Eur Urol Oncol. 2018. PMID: 31200843. doi:10.1016/j.euo.2018.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。